The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome

Authors

  • E. Diamanti-Kandarakis,

    Corresponding author
    1. Division of Endocrinology, First Department of Medicine, Laiko Hospital, Medical School, University of Athens, Athens;
      Associate Professor E Diamanti-Kandarakis, University of Athens, Medical School, 1A Zefyrou Str., Ekali 17562 Athens, Greece. E-mail: akandara@otenet.gr
    Search for more papers by this author
  • E. Kandaraki,

    1. York District Hospital, York, England, UK;
    Search for more papers by this author
  • C. Christakou,

    1. Division of Endocrinology, First Department of Medicine, Laiko Hospital, Medical School, University of Athens, Athens;
    Search for more papers by this author
  • D. Panidis

    1. Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Search for more papers by this author

Associate Professor E Diamanti-Kandarakis, University of Athens, Medical School, 1A Zefyrou Str., Ekali 17562 Athens, Greece. E-mail: akandara@otenet.gr

Summary

The polycystic ovary syndrome (PCOS), a prevalent endocrinopathy of women, has been associated with a clustering of adverse metabolic features, which co-exist with reproductive dysfunction. Lipid abnormalities are very common in lean as well as obese women with PCOS and should be cautiously considered in the therapeutic management of the syndrome. Clinicians should also critically assess the lipidemic effect of pharmaceutical intervention, primarily aimed at hyperandrogenism, anovulation or insulin resistance. Because dyslipidemia may contribute to long-term cardiometabolic and reproductive sequelae in PCOS, it should be considered as an additional therapeutic target when these patients are assigned to appropriate pharmaceutical treatment.

Ancillary